Search Results - technology+classifications+%3e+therapeutic+modalities

390 Results

Sort By:

Extracellular Vesicle mediated nucleic acid treatment in vivo

Value Proposition· Effective: animal studies showed increased survival and decreased tumor burden in liver cancer model.· Fewer side effects: no immunological reactions or off-target effects· Multiple targets: targets the cancer-stroma interactionsUnmet Need· Many current and pipeline cancer therapeutics, including therapeutic...

Published: 3/13/2025 | Inventor(s): Ling Li, Stephen Gould, Florin Selaru

Keywords(s): Drug Delivery Vehicle, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

A Novel and Unique Set of Human Antibodies to Human Resistin and to Human Resitin-like Molecule Beta (RELMB) that can be used to Target these Proteins in Human Disease

Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...

Published: 3/13/2025 | Inventor(s): Roger Johns

Keywords(s): Antibodies, Biologics, Cardiovascular Diseases, Disease Indication, Hypertension, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Hypertension

Compositions of Lipid Nanoparticles for Plasmid DNA Delivery to the Liver and Methods for Preparing the Same

Value Proposition:· Library screen of lipid nanoparticles to develop compositions for efficient transfection and tissue-specific delivery.· Selected high efficiency lipid nanoparticles for delivering plasmid DNA, siRNA, and mRNA. Technology Description· Researchers at Johns Hopkins have developed a multi-step screening method to...

Published: 3/14/2025 | Inventor(s): Hai-Quan Mao, Yining Zhu, Sashank Reddy, Ruochen Shen, Ivan Vuong, Jingyao Ma, Leonardo Cheng

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Multispecific Antibodies that Induce Downregulation of Programmed Death-ligand 1

Unmet Need: It is estimated that in 2018 there were more than 17 million new cases of cancer worldwide (see ACS). Immune checkpoint therapies have become a powerful treatment route for a wide variety of cancer types and have increased the life expectancy for patients whose disease is refractory to all other therapies. Due to variability in patient response...

Published: 3/14/2025 | Inventor(s): Jamie Spangler, Seth Ludwig, Angela Zhu, Rakeeb Kureshi, Helen Dooley

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies

Indole Lactate for the Treatment of Multiple Sclerosis

Unmet Need2.8 million people are estimated to be living with multiple sclerosis (MS) worldwide (35.9 per 100,000 population) (Walton et al.). The gold standard of care consists of symptom relieving remedies as well as disease modifying therapies. However, there are no curative therapies for MS, and most existing disease modifying therapies are only...

Published: 3/14/2025 | Inventor(s): Pavan Bhargava, Peter Calabresi, Michael Kornberg, Kathryn Fitzgerald

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology > Multiple Sclerosis

Polymeric Nanoparticle Compositions for Encapsulation and Sustained Release of Neuromodulators

JHU Ref #: C16591Value Proposition· Protein delivery system with tunable, sustained release profile, high payload capacity, and bioactivity retention· Neurotoxin release profile of at least 120 days· Scalable and translational manufacturing processUnmet Need· Neurotoxins are widely used in the aesthetic and therapeutic space. Among...

Published: 3/14/2025 | Inventor(s): Hai-Quan Mao, Sashank Reddy, Chenhu Qiu

Keywords(s):

Category(s): Technology Classifications, Technology Classifications > Therapeutic Modalities

Activating Mutations in GNAQ Sensitive to Antibiotic; Novel Molecular Pathway and Treatment Target for Capillary Malformations and Related Syndromes

Value Proposition: · Antibiotic treatment strategy for capillary malformations and Sturge-Weber Syndrome. · Selectively targets endothelial cells with the pathogenic GNAQ mutations using puromycin · Inhibits cell proliferation and reduces cell survival via activation of TRP6/NFAT signaling pathway · Compatible with various drug...

Published: 3/13/2025 | Inventor(s): Anne Comi, Jonathan Pevsner, Zhenhua Huang, Douglas Marchuk

Keywords(s): Biomarker, Disease Indication, Genetic Disorders, Mechanism-of-action Biomarker, Skin Disorders, Sturge-Weber Syndrome, Sturge-Weber Syndrome (SWS), Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Genetic Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Dermatology, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Dermatology > Sturge-Weber Syndrome

Self-Assembling Antiviral Prodrugs for Long-Acting Treatment of Chronic HIV Infections

Unmet Need / Invention Novelty: The need for long-acting HIV drugs arises from challenges such as pill burden, side effects, and stigma, which contribute to inconsistent use and reduced effectiveness. A long-acting antiretroviral formulation could enhance treatment adherence, reduce disease transmission, and better support populations facing barriers...

Published: 3/14/2025 | Inventor(s): Honggang Cui, Charles Flexner, Maya Monroe, Han Wang

Keywords(s):

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Infectious Diseases > HIV, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Infectious Diseases > Hepatitis B Virus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections

Novel Oxazolidinones for Treatment of Bacterial Infections

Marketing Summary DraftNovel Oxazolidinones for Treatment of Bacterial InfectionsJHU Ref #: C14633Value Proposition· Belong to the same chemical family as Zyvox, marketed by Pfizer, but shows better efficacy· Positive activity demonstrated against M. tuberculosis· MIC values the same or better than the current antibiotics in the...

Published: 3/13/2025 | Inventor(s): Gyanu Lamichhane, J. Ippoliti

Keywords(s): Bacterial Infections, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections

Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases

Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...

Published: 3/13/2025 | Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease

1 2 3 4 5 6 7 8 9 10 ...